Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olanzapine 2.5 mg Versus 5 mg Versus 10 mg in Highly Emetogenic Regimens: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

NCT07403370 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT07403370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07403370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olanzapine 2.5 mg Versus 5 mg Versus 10 mg in Highly Emetogenic Regimens: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Observational
Overall status
Completed
Start date
January 18, 2026
Completion date
March 30, 2026
Enrollment
2,493 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nausea and vomiting, olanzapine, solid tumours